Table 2.
Sample size and number of events for replication analyses
| Endpoint | THL Biobank | UK Biobank | UK Biobank subset |
|---|---|---|---|
| Number of events/N (%) | Number of events/N (%) | Number of events/N (%) | |
| All-cause mortality | 3 928/34 019 (11.55%) | 7 802/117 868 (6.62%) | 5 219/97 212 (5.37%) |
| Chronic kidney failure | 328/33 982 (0.97%) | 4 254/117 550 (3.62%) | 2 270/97 074 (2.34%) |
| COPD | 732/33 736 (2.17%) | 4 404/117 141 (3.76%) | 2 885/96 811 (2.98%) |
| Liver diseases | 417/33 783 (1.23%) | 2 696/117 328 (2.3%) | 1 884/96 828 (1.95%) |
| MACE | 4 640/31 754 (14.61%) | 6 511/115 745 (5.63%) | 4 311/96 885 (4.45%) |
| Diabetes | 2 703/31 565 (8.56%) | 6 836/115 579 (5.91%) | 3 376/96 746 (3.49%) |
UK Biobank subset represents subset excluding individuals with self-reported use of cholesterol lowering medication.
COPD chronic obstructive pulmonary disease, MACE major adverse cardiovascular event.